



ELSEVIER

Clinica Chimica Acta 273 (1998) 213-214



Author index

Volume 273 (1998)

- Adiloglu, A.K., Gurakur-Osborne, A., Prete, P.E., Standardized determination of apolipoprotein E phenotypes by simplified isoelectric focusing/immunoblotting in plasma and synovial fluid **273**, 99
- Ala-Houhala, I.O., see Koskinen, L.K. **273**, 69
- Asano, S., see Kikuchi, T. **273**, 1
- Aubert, A.-C., see Voirol, P. **273**, 89
- Babu, G.N., Bawari, M., Mathur, V.N., Kalita, J., Misra, U.K., Blood glutamate levels in patients with motor neuron disease **273**, 195
- Baumann, P., see Voirol, P. **273**, 89
- Bawari, M., see Babu, G.N. **273**, 195
- Berland, Y.F., see Gallice, P.M. **273**, 149
- Bing, X., see Qiaojia, H. **273**, 119
- Blöck, T.M., see Lang, W. **273**, 43
- Briand, G., see Fontaine, M. **273**, 161
- Brunet, P.J., see Gallice, P.M. **273**, 149
- Bydlowski, S.P., see Maeda, N.Y. **273**, 209
- Calcote, C.B., see Roberts, W.L. **273**, 21
- Carrère, J., Guy-Crotte, O., Figarella, C., Human pancreatic reg protein. Immunoenzymatic assay and molecular form in serum **273**, 185
- Cook, C.B., see Roberts, W.L. **273**, 21
- Crevat, A.D., see Gallice, P.M. **273**, 149
- Degand, P., see Fontaine, M. **273**, 161
- Divry, P., see Fontaine, M. **273**, 161
- Figarella, C., see Carrère, J. **273**, 185
- Fontaine, M., Briand, G., Largillière, C., Degand, P., Divry, P., Vianey-Saban, C., Mousson, B., Vamecq, J., Metabolic studies in a patient with severe carnitine palmitoyltransferase type II deficiency **273**, 161
- Gallice, P.M., Kovacic, H.N., Brunet, P.J., Berland, Y.F., Crevat, A.D., A non ouabain-like inhibitor of the sodium pump in uremic plasma ultrafiltrates and urine from healthy subjects **273**, 149
- Gordon, D.L., see Roberts, W.L. **273**, 21
- Gurakur-Osborne, A., see Adiloglu, A.K. **273**, 99
- Guy-Crotte, O., see Carrère, J. **273**, 185
- Hänseler, E., see Otto, V.I. **273**, 131
- Huang, C.-H., see Lan, F.-H. **273**, 13
- Ishiguro, I., see Shinohara, R. **273**, 171
- Jonzier-Perey, M., see Voirol, P. **273**, 89
- Kalita, J., see Babu, G.N. **273**, 195
- Kashiwabara, K., Nakamura, H., Kiguchi, T., Matsuoka, T., Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases **273**, 35
- Kiguchi, T., see Kashiwabara, K. **273**, 35
- Kikuchi, T., Kimata, S., Majima, K.-i., Asano, S., Determination of α -amylase using 4-O- β -D-galactopyranosylmaltotetraose (Gal-G4) as a substrate **273**, 1
- Kimata, S., see Kikuchi, T. **273**, 1
- Koivula, T.A., see Koskinen, L.K. **273**, 69
- Koskinen, L.K., Ala-Houhala, I.O., Lahtela, J.T., Laippala, P.J., Koivula, T.A., Does uremia interfere with HbA_{1c} results in the FPLC method with Mono S cation exchanger? **273**, 69
- Kovacic, H.N., see Gallice, P.M. **273**, 149
- Lahtela, J.T., see Koskinen, L.K. **273**, 69
- Laippala, P.J., see Koskinen, L.K. **273**, 69
- Lan, F.-H., Tang, Y.-C., Huang, C.-H., Wu, Y.-S., Zhu, Z.-Y., Antibody-based spot test for NADH-

- cytochrome b5 reductase activity for the laboratory diagnosis of congenital methemoglobinemia 273, 13
- Lang, W., Blöck, T.M., Zander, R., Solubility of NH_3 and apparent pK of NH_4^+ in human plasma, isotonic salt solutions and water at 37°C 273, 43
- Largillière, C., see Fontaine, M. 273, 161
- Li, L., see Qiaojia, H. 273, 119
- Lopes, A.A.B., see Maeda, N.Y. 273, 209
- Maeda, N.Y., Bydlowski, S.P., Lopes, A.A.B., Sialic acid content of von Willebrand factor subunit. A simple method for quantitative estimation 273, 209
- Majima, K.-i., see Kikuchi, T. 273, 1
- Manoharan, S., see Nagini, S. 273, 95
- Mathur, V.N., see Babu, G.N. 273, 195
- Matsuoka, T., see Kashiwabara, K. 273, 35
- Misra, U.K., see Babu, G.N. 273, 195
- Moore, M.L., see Roberts, W.L. 273, 21
- Moore, S., see Roberts, W.L. 273, 21
- Mousson, B., see Fontaine, M. 273, 161
- Nagini, S., Manoharan, S., Ramachandran, C.R., Lipid peroxidation and antioxidants in oral squamous cell carcinoma 273, 95
- Nakamura, H., see Kashiwabara, K. 273, 35
- Ohta, Y., see Shinohara, R. 273, 171
- O'Mullane, J., see Spillane, D.G. 273, 81
- Otto, V.I., Schär, B.K., Sulser, T., Hänseler, E., Specific determination of germ cell alkaline phosphatase for early diagnosis and monitoring of seminoma: performance and limitations of different analytical techniques 273, 131
- Pahwa, M.B., Seth, S., Seth, R.K., Lipid profile in various phases of menstrual cycle and its relationship with percentage plasma volume changes 273, 201
- Prasongwatana, V., see Sriboonlue, P. 273, 59
- Prete, P.E., see Adiloglu, A.K. 273, 99
- Qiaojia, H., Yuchai, T., Weiping, L., Shuxuan, Y., Xiaopeng, L., Bing, X., Yushui, W., Li, L., Zhongyong, Z., Qualitative bedside assay of increased human serum myoglobin by sandwich dot-immunogold filtration for the diagnosis of acute myocardial infarction 273, 119
- Ramachandran, C.R., see Nagini, S. 273, 95
- Roberts, W.L., Calcote, C.B., Cook, C.B., Gordon, D.L., Moore, M.L., Moore, S., Scheer, W.D., Snazelle, B.A., Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens 273, 21
- Rose, M.P., Follicle stimulating hormone. International standards and reference preparations for the calibration of immunoassays and bioassays 273, 103
- Schär, B.K., see Otto, V.I. 273, 131
- Scheer, W.D., see Roberts, W.L. 273, 21
- Seth, R.K., see Pahwa, M.B. 273, 201
- Seth, S., see Pahwa, M.B. 273, 201
- Shinohara, R., Ohta, Y., Yamauchi, M., Ishiguro, I., Improved fluorometric enzymatic sorbitol assay in human blood 273, 171
- Shuxuan, Yu., see Qiaojia, H. 273, 119
- Snazelle, B.A., see Roberts, W.L. 273, 21
- Spillane, D.G., O'Mullane, J., Development of an affinity-column-mediated enzyme-linked immunosorbent assay for ferritin 273, 81
- Sriboonlue, P., Suwantrai, S., Prasongwatana, V., An indirect method for urinary oxalate estimation 273, 59
- Sulser, T., see Otto, V.I. 273, 131
- Suwantrai, S., see Sriboonlue, P. 273, 59
- Tang, Y.-C., see Lan, F.-H. 273, 13
- Vamecq, J., see Fontaine, M. 273, 161
- Vianey-Saban, C., see Fontaine, M. 273, 161
- Voirol, P., Aubert, A.-C., Jonzier-Perey, M., Baumann, P., An automated procedure for the determination of protein concentration in subcellular fractions 273, 89
- Weiping, L., see Qiaojia, H. 273, 119
- Wu, Y.-S., see Lan, F.-H. 273, 13
- Xiaopeng, L., see Qiaojia, H. 273, 119
- Yamauchi, M., see Shinohara, R. 273, 171
- Yuchai, T., see Qiaojia, H. 273, 119
- Yushui, W., see Qiaojia, H. 273, 119
- Zander, R., see Lang, W. 273, 43
- Zhongyong, Z., see Qiaojia, H. 273, 119
- Zhu, Z.-Y., see Lan, F.-H. 273, 13



Subject index

Volume 273 (1998)

Acute myocardial infarction; Myoglobin; Dot-immunogold filtration assay; Enzyme-linked immunosorbent assay **273, 119**

Acylcarnitine; L-Carnitine; Carnitine palmitoyltransferase type II deficiency; Mass spectrometry **273, 161**

Alanine aminotransferase; Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase **273, 35**

Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Microalbumin; Urinary albumin **273, 21**

Ammonia; Solubility; Apparent pK; Human plasma; Isotonic salt solutions; Water **273, 43**

α -Amylase; 4-O- β -D-Galactopyranosylmaltotetraose **273, 1**

Amyotrophic lateral sclerosis; Glutamate; Motor neuron disease; Excitotoxins; Progressive bulbar palsy **273, 195**

Analysis; Microsomes; Proteins; Automation **273, 89**

Analytical methods; Albumin/creatinine ratio; Diabetic nephropathy; Method bias; Microalbumin; Urinary albumin **273, 21**

Apparent pK; Ammonia; Solubility; Human plasma; Isotonic salt solutions; Water **273, 43**

Aspartate aminotransferase; Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Alanine aminotransferase **273, 35**

Automation; Microsomes; Proteins; Analysis **273, 89**

Bioassays; Follicle stimulating hormone (FSH); Immunoassays; Standards; Therapeutics **273, 103**

Carbohydrate structure; Sialic acid; von Willebrand factor; Glycoproteins **273, 209**

L-Carnitine; Acylcarnitine; Carnitine palmitoyltransferase type II deficiency; Mass spectrometry **273, 161**

Carnitine palmitoyltransferase type II deficiency; Acylcarnitine; L-Carnitine; Mass spectrometry **273, 161**

Chromatography, liquid; Hemoglobin A, glycosylated; Hemodialysis; *Diabetes mellitus* **273, 69**

Column regeneration; ELISA; Non-competitive; Enzyme amplification **273, 81**

Diabetes; Sorbitol; Sorbitol dehydrogenase; Human blood **273, 171**

Diabetes mellitus; Hemoglobin A, glycosylated; Hemodialysis; Chromatography, liquid **273, 69**

- Diabetic nephropathy;** Albumin/creatinine ratio; Analytical methods; Method bias; Microalbumin; Urinary albumin 273, 21
- Diagnostic specificity;** Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay 273, 131
- Dot-immunogold filtration assay;** Myoglobin; Acute myocardial infarction; Enzyme-linked immunosorbent assay 273, 119
- ELISA;** Non-competitive; Column regeneration; Enzyme amplification 273, 81
- ELISA;** Reg; Human; Pancreatic juice; Serum 273, 185
- Enzyme activity;** NADH-cytochrome b5 reductase; Monoclonal antibody; Nitrocellulose; Recessive congenital methemoglobinemia 273, 13
- Enzyme amplification;** ELISA; Non-competitive; Column regeneration 273, 81
- Enzyme-linked immunosorbent assay;** Myoglobin; Acute myocardial infarction; Dot-immunogold filtration assay 273, 119
- Excitotoxins;** Glutamate; Motor neuron disease; Amyotrophic lateral sclerosis; Progressive bulbar palsy 273, 195
- Follicle stimulating hormone (FSH);** Immunoassays; Standards; Bioassays; Therapeutics 273, 103
- 4-O- β -n-Galactopyranosylmaltotetraose;** α -Amylase 273, 1
- Germ cell alkaline phosphatase;** Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay; Diagnostic specificity 273, 131
- Glutamate;** Motor neuron disease; Excitotoxins; Amyotrophic lateral sclerosis; Progressive bulbar palsy 273, 195
- Glycoproteins;** Sialic acid; von Willebrand factor; Carbohydrate structure 273, 209
- Hematocrit;** Menstrual cycle; Lipid profile; Plasma volume; Hemoglobin 273, 201
- Hemodialysis;** Hemoglobin A, glycated; Chromatography, liquid; *Diabetes mellitus* 273, 69
- Hemodialysis;** Tumor marker; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Aspartate aminotransferase; Alanine aminotransferase 273, 35
- Hemoglobin A, glycated;** Hemodialysis; Chromatography, liquid; *Diabetes mellitus* 273, 69
- Hemoglobin;** Menstrual cycle; Lipid profile; Plasma volume; Hematocrit 273, 201
- Human blood;** Sorbitol; Sorbitol dehydrogenase; Diabetes 273, 171
- Human plasma;** Ammonia; Solubility; Apparent pK; Isotonic salt solutions; Water 273, 43
- Human;** Reg; Pancreatic juice; Serum; ELISA 273, 185
- Immunoassays;** Follicle stimulating hormone (FSH); Standards; Bioassays; Therapeutics 273, 103
- Immunoassay;** Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Ion exchange chromatography; Diagnostic specificity 273, 131
- Ion exchange chromatography;** Germ cell alkaline phosphatase; Seminoma; Two-dimensional electrophoresis; Immunoassay; Diagnostic specificity 273, 131
- Isotonic salt solutions;** Ammonia; Solubility; Apparent pK; Human plasma; Water 273, 43
- Lipid profile;** Menstrual cycle; Plasma volume; Hematocrit; Hemoglobin 273, 201
- Liver cirrhosis;** Tumor marker; Non-insulin-dependent diabetes mellitus; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase 273, 35
- Mass spectrometry;** Acylcarnitine; L-Carnitine; Carnitine palmitoyltransferase type II deficiency 273, 161
- Menstrual cycle;** Lipid profile; Plasma volume; Hematocrit; Hemoglobin 273, 201

- Method bias**; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Microalbumin; Urinary albumin 273, 21
- Microalbumin**; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Urinary albumin 273, 21
- Microsomes**; Proteins; Automation; Analysis 273, 89
- Monoclonal antibody**; NADH-cytochrome b5 reductase; Enzyme activity; Nitrocellulose; Recessive congenital methemoglobinemia 273, 13
- Motor neuron disease**; Glutamate; Excitotoxins; Amyotrophic lateral sclerosis; Progressive bulbar palsy 273, 195
- Myoglobin**; Acute myocardial infarction; Dot-immunogold filtration assay; Enzyme-linked immunosorbent assay 273, 119
- NADH-cytochrome b5 reductase**; Enzyme activity; Monoclonal antibody; Nitrocellulose; Recessive congenital methemoglobinemia 273, 13
- Nitrocellulose**; NADH-cytochrome b5 reductase; Enzyme activity; Monoclonal antibody; Recessive congenital methemoglobinemia 273, 13
- Non-competitive**; ELISA; Column regeneration; Enzyme amplification 273, 81
- Non-insulin-dependent diabetes mellitus**; Tumor marker; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase 273, 35
- Ouabain**; Sodium pump inhibitor; Uremia 273, 149
- Oxalate determination**; Oxalate estimation 273, 59
- Oxalate estimation**; Oxalate determination 273, 59
- Pancreatic juice**; Reg; Human; Serum; ELISA 273, 185
- Plasma volume**; Menstrual cycle; Lipid profile; Hematocrit; Hemoglobin 273, 201
- Progressive bulbar palsy**; Glutamate; Motor neuron disease; Excitotoxins; Amyotrophic lateral sclerosis 273, 195
- Proteins**; Microsomes; Automation; Analysis 273, 89
- Recessive congenital methemoglobinemia**; NADH-cytochrome b5 reductase; Enzyme activity; Monoclonal antibody; Nitrocellulose 273, 13
- Reg**; Human; Pancreatic juice; Serum; ELISA 273, 185
- Seminoma**; Germ cell alkaline phosphatase; Two-dimensional electrophoresis; Ion exchange chromatography; Immunoassay; Diagnostic specificity 273, 131
- Serum**; Reg; Human; Pancreatic juice; ELISA 273, 185
- Sialic acid**; von Willebrand factor; Glycoproteins; Carbohydrate structure 273, 209
- Sodium pump inhibitor**; Uremia; Ouabain 273, 149
- Solubility**; Ammonia; Apparent pK; Human plasma; Isotonic salt solutions; Water 273, 43
- Sorbitol dehydrogenase**; Sorbitol; Diabetes; Human blood 273, 171
- Sorbitol**; Sorbitol dehydrogenase; Diabetes; Human blood 273, 171
- Standards**; Follicle stimulating hormone (FSH); Immunoassays; Bioassays; Therapeutics 273, 103
- Therapeutics**; Follicle stimulating hormone (FSH); Immunoassays; Standards; Bioassays 273, 103
- Tumor marker**; Non-insulin-dependent diabetes mellitus; Liver cirrhosis; Hemodialysis; Aspartate aminotransferase; Alanine aminotransferase 273, 35
- Two-dimensional electrophoresis**; Germ cell alkaline phosphatase; Seminoma; Ion exchange chromatography; Immunoassay; Diagnostic specificity 273, 131

Uremia; Sodium pump inhibitor; Ouabain 273, 149

Urinary albumin; Albumin/creatinine ratio; Analytical methods; Diabetic nephropathy; Method bias; Microalbumin 273, 21

Water; Ammonia; Solubility; Apparent p*K*; Human plasma; Isotonic salt solutions 273, 43

von Willebrand factor; Sialic acid; Glycoproteins; Carbohydrate structure 273, 209

